Prescribing guide: individualising medicines use for people with type 2 diabetes
Resource impact
A resource impact summary report and resource impact template have been published alongside NICE's guideline on type 2 diabetes in adults. These cover the resource implications of recommendations that represent a change to current practice. The summary report includes a table that shows the treatment costs and savings (from a reduction in events) for every additional 10,000 people treated over a 3-year period with the following medicines in the following groups:
-
SGLT-2 inhibitors in people with type 2 diabetes
-
Semaglutide (subcutaneous) in people with type 2 diabetes and atherosclerotic cardiovascular disease
-
GLP-1 receptor agonists or tirzepatide in people with early onset type 2 diabetes.
ISBN: 978-1-4731-9304-8
This page was last updated: